25.08.2020
On August 25, 2010, Dr. Ahmed Sheriff together with Birgit Vogt, Dr. Rudolf Kunze, Stephan Hiller and Dr. Bernd Wegener founded Pentracor GmbH to implement the idea of CRP apheresis for acute inflammation-driven diseases such as myocardial infarction.
Hennigsdorf, June 8, 2020 - The medical technology company Pentracor GmbH, operating in the dynamically growing healthcare sector, has almost completed the placement of its corporate bond with a possible conversion right (ISIN: DE000A289XB9, WKN: A289XB) via private placement with an issue volume of EUR 15 million. Final discussions with potential investors are still ongoing.
07.06.2020
In the American Journal of Case Reports the application of PentraSorb® CRP in a COVID-19 patient published.
25.05.2020 - In an interview with the corporate bond portal BondGuide, company founder and CEO Ahmed Sheriff talks about the reasons for the bond issue and the company's business plan:
New issue of Pentracor: "We are the first and so far the only ones who have succeeded".
22.05.2020 - In an interview with the bond platform Bond Finder, company founder Ahmed Sheriff talks about the background to the bond issue and explains why going to the capital market is the next logical step in the company's development:
„Our medical device innovation is unrivalled" - Interview with Dr. Ahmed Sheriff, Pentracor GmbH
22 May 2020 - In an interview with the stock market portal 4investors, Pentracor CEO Ahmed Sheriff and CFO Sven Haevernick explain their plans for the new bond, the future corporate goals and the global market potential of PentraSorb® CRP:
"Pentracor: IPO would be a logical step - FMC among investors"
Hennigsdorf, May 20, 2020 - The medical technology company Pentracor GmbH, based in Hennigsdorf near Berlin and operating in the dynamically growing healthcare sector, is issuing a bond with a possible conversion right (ISIN: DE000A289XB9, WKN: A289XB) via private placement. The issue volume is up to EUR 15 million, the interest rate is fixed at 8.50% p.a., the term of the bond is 5 years.
15.04.2020
In the programme of 15 April 2020, CRP apheresis was presented as an option for the treatment of COVID-19. Furthermore, Professor Garlichs, Chief Physician of the Medical Clinic - Internal Medicine of the Diakonissenkrankenhaus in Flensburg, presented the results of the CAMI 1 study. The approx.
28.02.2020
Another case report on CRP apheresis was published in the journal Blood purification über die CRP-Aphererse veröffentlicht.
